改良ProMACE-CytaBOM方案治疗复发、难治侵袭性NHL的疗效评价

目的评价改良ProMACE-CytaBOM方案治疗复发、难治侵袭性NHL的疗效及安全性。方法回顾性分析2005年5月至2010年9月期间,我院收治的27例复发、难治性侵袭性淋巴瘤患者,其中男19例,女8例,中位年龄47（15～74）岁;均采用改良ProMACE-CytaBOM方案;21天为1周期。结果 27例患者均可评价疗效,总有效率51.8%（完全缓解率22.2%）。中位无进展生存期为7月,中位总生存期为19月。B细胞、LDH正常NHL患者中位无进展生存期长于T细胞、LDH高者,差异均有统计学意义（P〈0.05）。B细胞、IPI≤2、LDH正常的NHL患者中位总生存期长于T细胞、IPI〉2、...

Full description

Saved in:
Bibliographic Details
Published in肿瘤防治研究 Vol. 39; no. 2; pp. 201 - 204
Main Author 俸艳英 胡晓桦 刘志辉 李永强 廖小莉
Format Journal Article
LanguageChinese
Published 2012
Subjects
侵袭性非霍奇金淋巴瘤
复发
改良ProMACE-CytaBOM方案
难治
Online AccessGet full text
ISSN1000-8578

Cover

More Information
Summary:目的评价改良ProMACE-CytaBOM方案治疗复发、难治侵袭性NHL的疗效及安全性。方法回顾性分析2005年5月至2010年9月期间,我院收治的27例复发、难治性侵袭性淋巴瘤患者,其中男19例,女8例,中位年龄47（15～74）岁;均采用改良ProMACE-CytaBOM方案;21天为1周期。结果 27例患者均可评价疗效,总有效率51.8%（完全缓解率22.2%）。中位无进展生存期为7月,中位总生存期为19月。B细胞、LDH正常NHL患者中位无进展生存期长于T细胞、LDH高者,差异均有统计学意义（P〈0.05）。B细胞、IPI≤2、LDH正常的NHL患者中位总生存期长于T细胞、IPI〉2、LDH高者,差异均有统计学意义（P〈0.05）。不良反应主要有Ⅱ～Ⅲ度血液学毒性及Ⅰ～Ⅱ度非血液学毒性,6例并发轻度感染,经一般抗生素治疗可控制。结论 ProMACE-CytaBOM改良方案治疗复发、难治侵袭性NHL疗效肯定,不良反应可耐受,值得进一步研究。
Bibliography:42-1241/R
Objective To evalute the efficacy and safety of modified ProMACE-CytaBOM regimen for relapsed or refractory patients with aggressive NHL.Methods Twenty-seven patients with relapsed or refractory NHL from May 2005 to September 2010 were retrospectively analyzed.They were 19 male and 8 female patients with meadian age of 47 years（range 15 to 74） years old.All patients were treated by modified ProMACE-CytaBOM cycles were repeated every 21 days.Results The overall response rates of all patients were 51.9%（CR 22.2%）.The median progression-free survival（PFS） was 7 months and the median overall survival（OS） was 19 months.The median PFS was longer in subgroups patients with B-cell and normal LDH NHL than that in those with T-cell and elevated serum LDHNHL.The median OS was longer in subgroups patients with B-cell,IPI≤2 and normal LDH than that in those with T-cell,IPI2 and elevated serum LDHNHL.The major side effects were Ⅱ～Ⅲ grades of bone marrow suppression and Ⅰ～Ⅱ grades of non-myeloid toxicities.Conclusi
ISSN:1000-8578